Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.665 USD | -0.56% | -8.87% | -18.22% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.22% | 48.38M | |
+24.96% | 46.71B | |
+48.83% | 41.8B | |
-1.21% | 41.52B | |
-5.86% | 29.55B | |
+10.32% | 25.78B | |
-20.81% | 19.26B | |
+1.98% | 12.14B | |
-3.34% | 12.08B | |
+28.08% | 11.98B |
- Stock Market
- Equities
- GANX Stock
- News Gain Therapeutics, Inc.
- Gain Therapeutics Names Gene Mack as CFO